Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Oral Vitamin C Supplementation Modulates Inflammatory Cytokines in Clonal Cytopenia of Undetermined Significance and Low-Risk Myeloid Malignancies: Results from EVI-2 Trial

Ali Al-Mousawi, Stine Ulrik Mikkelsen, Amalie Bach Nielsen, Anders Pommer Vallentin, Astrid Ø. Mortensen, Zachary Madaj, Jakob Jespersen, Linn Gillberg, Jakob Werner Hansen, Mette Klarskov Andersen, Bo Mortensen, Marianne Tang Severinsen, Casey O'Connell, Jens Lykkesfeldt, Peter A. Jones, Kirsten Gronbaek

Blood (2024) 144 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2024-201437

Published: 2024

Journal Articles

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2022) 140 (Supplement 1): 579–582.

https://doi.org/10.1182/blood-2022-160384

Published: 2022

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2021) 138 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2021-148668

Published: 2021

Journal Articles

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard Wells, James McCloskey, II, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona

Blood (2020) 136 (6): 674–683.

https://doi.org/10.1182/blood.2019004143

Published: 2020

Journal Articles

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Blood (2020) 135 (19): 1696–1703.

https://doi.org/10.1182/blood.2019003347

Published: 2020

Includes: Supplemental data

Journal Articles

The TEMPI syndrome

David B. Sykes, Casey O’Connell, Wilfried Schroyens

Blood (2020) 135 (15): 1199–1203.

https://doi.org/10.1182/blood.2019004216

Published: 2020

Includes: Supplemental data

Journal Articles

Comprehensive Molecular Profiling of Idiopathic Erythrocytosis By Genetic Ancestry

Caitlin O'Neill, MD, Zarko Manojlovic, PhD BS, Ah-Reum Jeong, MD, Yili Xu, MS, Yuxin Jin, MS, Sharon Chang, BS, Eric Kwok, BS, Michelle Webb, MS, Casey O'Connell, MD

Blood (2019) 134 (Supplement_1): 945.

https://doi.org/10.1182/blood-2019-122619

Published: 2019

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD

Blood (2018) 132 (Supplement 1): 353.

https://doi.org/10.1182/blood-2018-99-111338

Published: 2018

Journal Articles

How I treat incidental pulmonary embolism

Casey O’Connell

Blood (2015) 125 (12): 1877–1882.

https://doi.org/10.1182/blood-2014-08-551879

Published: 2015

Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2014) 124 (21): 529.

https://doi.org/10.1182/blood.V124.21.529.529

Published: 2014

Journal Articles

Romiplostim For Thrombocytopenia in Patients with Hepatitis C (HCV)-Associated Liver Disease: Preliminary Report Of An Ongoing Clinical Trial

Howard Liebman, MD, Laurie Hornor, BA, Tse-Ling Fong, MD, Casey O'Connell, MD, Ilene C Weitz, MD

Blood (2013) 122 (21): 3555.

https://doi.org/10.1182/blood.V122.21.3555.3555

Published: 2013

Journal Articles

Ethnic and Racial Difference In H.Pylori Infection In Patients With ITP Treated At A MAJOR Tertiary Medical Center In LOS Angeles

Caitlin M O'Neill, BA, Ulysses Gomez, BA, Ilene C Weitz, MD, Casey O'Connell, MD, Howard Liebman, MD

Blood (2013) 122 (21): 3548.

https://doi.org/10.1182/blood.V122.21.3548.3548

Published: 2013

Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Blood (2013) 122 (21): 1548.

https://doi.org/10.1182/blood.V122.21.1548.1548

Published: 2013

Journal Articles

Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma

Sikander Ailawadhi, M.D., Howard A Liebman, MD, Susan Groshen, PhD, Denice D. Tsao-Wei, PhD, Leanne Rochanda, MS, Ibrahim Aldoss, MD, Casey O'Connell, MD, Teresa Wang, Christine Duran, Frederick Rickles, MD, FACP

Blood (2013) 122 (21): 5350.

https://doi.org/10.1182/blood.V122.21.5350.5350

Published: 2013

Journal Articles

Autoimmune Myelofibrosis (AIMF) – Clinical Features, Course and Outcome

Caroline Irene Piatek, M.D., Maria E. Vergara-Lluri, M.D., Vinod Pullarkat, MD, Imran N. Siddiqi, M.D, Ph.D., Casey O'Connell, MD, Donald I. Feinstein, MD, Russell K. Brynes, MD

Blood (2013) 122 (21): 3714.

https://doi.org/10.1182/blood.V122.21.3714.3714

Published: 2013

Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Blood (2013) 122 (21): 497.

https://doi.org/10.1182/blood.V122.21.497.497

Published: 2013

NARROW

Oral Vitamin C Supplementation Modulates Inflammatory Cytokines in Clonal Cytopenia of Undetermined Significance and Low-Risk Myeloid Malignancies: Results from EVI-2 Trial

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

The TEMPI syndrome

Comprehensive Molecular Profiling of Idiopathic Erythrocytosis By Genetic Ancestry

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

How I treat incidental pulmonary embolism

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Romiplostim For Thrombocytopenia in Patients with Hepatitis C (HCV)-Associated Liver Disease: Preliminary Report Of An Ongoing Clinical Trial

Ethnic and Racial Difference In H.Pylori Infection In Patients With ITP Treated At A MAJOR Tertiary Medical Center In LOS Angeles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma

Autoimmune Myelofibrosis (AIMF) – Clinical Features, Course and Outcome

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only